Andrew Kaplan, MD
Cardiovascular Disease · Mesa, AZNPI 1154399343
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Impulse Dynamics (USA) Inc. at 57.3% of the total. Reporting peaked in 2023 at $79,061 and has fallen 87.5% since, to $9,850 in 2025. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 571 payments — averaging $356.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Impulse Dynamics (USA) Inc.$117K
- Avertix Medical, Inc$61K
- E.r. Squibb & Sons, L.L.C.$4K
- Biosense Webster, Inc.$4K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
- Pfizer$3K
- plus $12K from 37 others
Across 87 payments — averaging $2887.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Impulse Dynamics (USA) Inc.$116K
- Boston Scientific$55K
- Medtronic$48K
- Abbott$25K
- Amarin Pharma, Inc.$7K
What the payments were for
- Consulting fees$87,46843%
- Speaking & faculty fees$78,75439%
- Travel & lodging$14,9167%
- Food & beverage$22,24211%
- Education$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$174,734
- OPTIMIZER SMART SYSTEM$24,777
- ELIQUIS$6,125
- LifeVest$2,661
- Carto 3$2,382
- GENERAL - THERAPIES$553
- CARDIOMEMS$358
- Abre$295
- COBALT DR MRI SURESCAN$291
- Carnation Ambulatory Monitor$235
- Confirm Rx$180
- Micra$174
- S-ICD System Magnet$150
- OCTARAY MAPPING CATHETER$149
- LINQ II$140
- COREVALVE EVOLUT R$135
- Inspire$133
- Admiral Xtreme$130
- Inpefa$125
- QDOT MICRO Catheter$122
How this compares
$203,509 in reported general payments places this provider in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 171 | $166,446 |
| EntrestoSacubitril/Valsartan | 86 | $85,730 |
| MultaqDronedarone Hcl | 49 | $56,175 |
| FarxigaDapagliflozin Propanediol | 57 | $47,598 |
| XareltoRivaroxaban | 35 | $32,196 |
| JardianceEmpagliflozin | 34 | $29,590 |
| Propafenone Hcl ErPropafenone Hcl | 45 | $4,693 |
| Verapamil ErVerapamil Hcl | 112 | $3,552 |
| Flecainide Acetate | 114 | $2,865 |
| Verapamil SrVerapamil Hcl | 71 | $2,847 |
| SotalolSotalol Hcl | 167 | $2,753 |
| Amiodarone Hcl | 178 | $2,606 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 17 | $2,304 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 79 | $1,928 |
| Metoprolol Succinate | 191 | $1,882 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $2,892 | $166,446171 claims |
| NovartisEntresto | $143 | $85,73086 claims |
| Sanofi-aventis U.S. LLCMultaq | $84 | $56,17549 claims |
| AstraZenecaFarxiga | $135 | $47,59857 claims |
| Johnson & JohnsonXarelto | $133 | $32,19635 claims |
| Boehringer IngelheimJardiance | $118 | $29,59034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Mesa
- Rodrigo ChanMesa$81K
- Edgardo Zavala AlarconMesa$72K
- Amy DalimanMesa$67K
- Charles JostMesa$50K
- Santosh DesaiMesa$26K
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Krishnaswami VijayaraghavanScottsdale$927K
- Steven MottlTucson$340K
- Paul UnderwoodScottsdale$259K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.